LYMA enters gut health category with ID² launch

British medical technology brand LYMA has launched its first gut health supplement, LYMA ID², marking the company's entry into a new product category. 

The supplement will also arrive at Harrods' fifth-floor Wellness Clinic later this week through an exclusive UK retail partnership that reinforces the brand's premium, science-led positioning.

LYMA describes the new supplement as a "four-dimensional gut formula" that addresses gut microbiome health, cellular integrity, mineral absorption and systemic resilience in a single daily dose.

The formula delivers 8.5g of prebiotic fibre from four fibre types, compared with less than 4g in most diets, according to the company. It also contains algae-derived omega-3 and over 25 bioavailable chelated vitamins and minerals.

The gut health launch extends LYMA's premium wellness range and marks the latest category extension for the company, which was founded by Lucy Goff in 2018.

The company began with a supplement formulated with peer-reviewed, patented ingredients, before moving into devices with the LYMA Laser in 2020, which was named a Time Magazine World's Best Invention.

Skincare followed in 2023 with the launch of two products that introduced "groundbreaking" epigenetic innovation, while earlier this year the brand introduced an AI-powered skin analysis app.

Professor Paul Clayton, LYMA's director of science and a specialist in pharmaco-nutrition, said the brand's formula was designed to address gaps he sees in the existing gut health market.

"Most probiotic supplements don't contain any prebiotics at all, and if they do it's nowhere near enough," Clayton commented.

"As a result, once you've swallowed them, the bacteria can't stick around. They can't colonise and have an effect. A probiotic without prebiotics is not a gut supplement at all."

Clayton also pointed to mineral bioavailability as a formulation priority, saying many supplements use oxide-form minerals with poor absorption rates. LYMA ID² uses chelated minerals bound to amino acids, which the company says deliver higher absorption.

The brand is also positioning ID² as a companion product for consumers using GLP-1 weight-loss medications, arguing that reduced food intake can create gaps in fibre, omega-3 and mineral consumption.

LYMA reported revenues of £36 million for the year ending 31 December 2025, with the US now accounting for more than 70% of global sales following its expansion into that market.